Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
14.75
+0.52 (3.65%)
At close: Jan 27, 2026, 4:00 PM EST
14.76
+0.01 (0.07%)
Pre-market: Jan 28, 2026, 6:32 AM EST
Tenax Therapeutics Employees
As of December 31, 2024, Tenax Therapeutics had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$7,221,000
Market Cap
598.41M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 6 | 0 | - | 4 | 2 |
| Dec 31, 2023 | 6 | -2 | -25.00% | 5 | 1 |
| Dec 31, 2022 | 8 | -1 | -11.11% | 7 | 1 |
| Dec 31, 2021 | 9 | -1 | -10.00% | 8 | 1 |
| Dec 31, 2020 | 10 | 0 | - | 9 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| Keros Therapeutics | 169 |
| Alpha Tau Medical | 125 |
| Lexicon Pharmaceuticals | 103 |
| Invivyd | 100 |
| CorMedix | 65 |
| Altimmune | 59 |
| Design Therapeutics | 54 |
TENX News
- 19 days ago - Tenax Therapeutics: A Speculative Buy - Seeking Alpha
- 22 days ago - Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing - Seeking Alpha
- 5 weeks ago - Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment - GlobeNewsWire
- 2 months ago - Tenax Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Tenax Therapeutics, Inc. (TENX) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF Transcript - Seeking Alpha
- 2 months ago - Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF - GlobeNewsWire
- 3 months ago - Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire